|
Skinvisible Inc
SKVI's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Skinvisible Inc 's sales fell
by 0 % in the first quarter of 2025 from the same quarter a year ago.
Ranking at No. 1756
Major Pharmaceutical Preparations industry recorded
growth of revenues by 4.44 %
Skinvisible Inc net loss decreased from $0 millions, to $0 millions in first quarter of 2025,
• More on SKVI's Growth
|
|
Skinvisible Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 202.41 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 53.63.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.45.
• More on SKVI's Valuation
|
|
|
|
|
Skinvisible Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 202.41 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 53.63.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.45.
• More on SKVI's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com